Clinical Trials Logo

Other clinical trials

View clinical trials related to Other.

Filter by:

NCT ID: NCT03408639 Completed - Clinical trials for Anemia in End-Stage Renal Disease

Comparing Efficacy and Safety of CinnaGen Beta Erythropoietin (CinnaPoietin®) Versus Eprex® on the Treatment of Anemia in ESRD Hemodialysis Patients

Start date: June 22, 2016
Phase: Phase 3
Study type: Interventional

This Phase III, randomized, two-armed, parallel, double-blind, active-controlled clinical trial is designed to compare efficacy and safety of CinnaPoietin® (Beta erythropoietin) and Eprex® (epoetin alpha) on the treatment of anemia in 156 End-Stage Renal Disease hemodialysis patients. 156 patients have been planned to randomize and assign to receive CinnaPoietin® or Eprex® for a 26-week period. Administration dose for patients who are treated with erythropoietin is the similar dose of the previously administered amount (IV or SC without any change). After then, dose adjustment will be made based on patients' response. The primary objective of this study is to compare the efficacy of CinnaPoietin® with Eprex®. The secondary objectives of this study are further comparison and evaluation of efficacy along with safety between CinnaPoietin® and Eprex®.

NCT ID: NCT03408327 Completed - Schizophrenia Clinical Trials

The Application of Wearable Technology to Improve the Physical Activity Level of People With Chronic Mental Illness

Start date: March 16, 2018
Phase: N/A
Study type: Interventional

The object is to develop a physical activity promotion program by applying social cognitive theory and wearable technology and evaluate its feasibility in people with MI Stage I: Accuracy, Acceptability, Feasibility. Stage II: Effectiveness Analysis In stage II, will conduct a single-blinded, randomized controlled study. 90 participants will be randomly assigned to experimental group or control group. The intervention for both groups will last for 12 weeks, with a 12-week of follow-up. The measurements include physical activity level, physical fitness, cognitive function and sleep quality, as well as the moderators of the effectiveness of program.

NCT ID: NCT03407898 Completed - Clinical trials for Mallampati Score, Difficult Intubation, Videolaryngoscope

The Effect of Different Videolaryngoscopes on Intubation Success in Difficult Airway Patients

Start date: May 2, 2018
Phase:
Study type: Observational [Patient Registry]

Mallampati score > 3 generally indicate difficult airway and difficult intubation. Most anesthesiologist usually use this score system to predict difficult airway management. Different laryngoscopes may be useful in management of difficult airway. This study designed to compare different videolaryngoscopes in intubation success in patient of Mallampati score>3.

NCT ID: NCT03407716 Completed - Cancer Survivor Clinical Trials

Ginseng in Decreasing Cancer-Related Fatigue After Treatment in Cancer Survivors

Start date: March 1, 2019
Phase: Early Phase 1
Study type: Interventional

This randomized pilot trial studies how well North American ginseng extract AFX-2 (ginseng) works in decreasing cancer-related fatigue after treatment in cancer survivors. Ginseng may decrease fatigue in people who were treated for cancer.

NCT ID: NCT03407534 Completed - Diarrhea Clinical Trials

Detection of Exocrine Pancreatic Insufficiency in Patients With Diarrhea and Bloating

Start date: November 2015
Phase:
Study type: Observational

The prevalence of exocrine pancreatic insufficiency (EPI) among patients presenting with diarrhea and bloating as their chief complaints is not well studied. Diarrhea and or bloating can be due to different etiologies such as celiac disease and irritable bowel syndrome. However, concomitant EPI can exacerbate these conditions, or be the main cause of the symptoms. Furthermore, some of these diagnoses can be epiphenomena or consequences of EPI. The Investigators hypothesize that EPI will be detected in significant proportion of patients with bloating or diarrhea and that early detection and management of EPI can prevent unnecessary work up for other causes of diarrhea.

NCT ID: NCT03407391 Completed - Parenting Clinical Trials

Antecedent Picky Eating Behaviour in Young Children

Start date: April 1, 1991
Phase: N/A
Study type: Observational

Picky eating behaviour in young children is a very common concern for parents. The aim of the study is to investigate factors during early life which are associated with a child becoming a picky eater.

NCT ID: NCT03407105 Completed - Clinical trials for Human Immunodeficiency Virus (HIV)

A Dose-Escalation Study of MDX-010 Administered Monthly as Immunotherapy in Subjects Infected With Human Immunodeficiency Virus (HIV)

Start date: April 21, 2003
Phase: Phase 1
Study type: Interventional

The purpose of this study is to assess the safety and tolerability of 2 or 4 doses of MDX-010 in HIV-infected subjects

NCT ID: NCT03406962 Completed - Clinical trials for Inherited Metabolic Disorders (IMD)

MGTA-456 in Patients With Inherited Metabolic Disorders Undergoing Hematopoietic Stem Cell Transplantation (HSCT)

Start date: February 9, 2018
Phase: Phase 2
Study type: Interventional

This study is designed to assess the safety and efficacy of using MGTA-456 in patients with Inherited Metabolic Disorders (IMD) undergoing stem cell transplantation.

NCT ID: NCT03406871 Completed - Clinical trials for Advanced and Metastatic Solid Tumor

Regorafenib and Nivolumab Simultaneous Combination Therapy

REGONIVO
Start date: January 25, 2018
Phase: Phase 1/Phase 2
Study type: Interventional

the efficacy and safety ofhe use of regorafenib in combination with nivolumab

NCT ID: NCT03406858 Completed - Clinical trials for Castration-Resistant Prostate Carcinoma

Pembro and HER2Bi-Armed Activated T Cells in Treating Patients With Metastatic Castration Resistant Prostate Cancer

Start date: June 7, 2018
Phase: Phase 2
Study type: Interventional

This phase II trial studies how well pembrolizumab and HER2Bi-armed activated T cells work in treating patients with castration resistant prostate cancer that has spread to other places in the body. Monoclonal antibodies, such as pembrolizumab, may interfere with the ability of tumor cells to grow and spread. HER2Bi-armed activated T cells are made using T cells and may target and kill cancer cells. Giving pembrolizumab and HER2Bi-armed activated T cells may work better in treating patients with castration resistant prostate cancer.